Ozempic® approved in the US for CV risk reduction in people with type 2 diabetes ... Read more


Financial calendar 2020 ... Read more


Ozempic® approved in the US for CV risk reduction in people with type 2 diabetes ... Read more


Novo Nordisk A/S – Share repurchase programme ... Read more


Financial calendar 2020 ... Read more


Novo Nordisk A/S – Share repurchase programme ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations
Press material is intended for media.


Novo Nordisk Media

Novo Nordisk and UNICEF partner to help prevent childhood overweight and obesity

20 November - Novo Nordisk and UNICEF have announced a new partnership to help prevent childhood overweight and obesity worldwide with an initial focus on interventions in Latin America and the Caribbean.

Under this partnership, the United Nations children’s agency and the global healthcare company will combine efforts to enhance knowledge and awareness on how to prevent overweight and obesity and address their root causes. The partnership will initially cover a period of three years.

“There is no doubt that childhood overweight and obesity is a public health crisis that requires immediate attention. Childhood overweight and obesity is more than an individual choice, this is everybody’s business. Together with UNICEF, we hope to help millions of children lead healthy lives and at the same time ease the burden of obesity to society,” said Novo Nordisk President and CEO Lars Fruergaard Jørgensen.

Read the full press release on the partnership

Read UNICEF's release


Dicerna and Novo Nordisk enter agreement to discover and develop RNAi therapies for liver-related cardio-metabolic diseases 

18 November - Novo Nordisk and Dicerna today announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration plans to explore more than 30 liver cell targets and may deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases. Dicerna will conduct and fund discovery and preclinical development to clinical candidate selection for each liver cell target, and Novo Nordisk will be responsible for all further development.

“Through this important collaboration with Dicerna, we gain access to an innovative technology and deep expertise in RNA interference,” said Marcus Schindler, senior vice president of Global Drug Discovery in Novo Nordisk. “Dicerna is the ideal partner to discover and develop molecules for targets that may yield multiple potential treatments across disease areas such as diabetes, obesity, cardiovascular and NASH. We will work closely together to unlock the true potential of treating a range of diseases using RNAi therapies, for the benefit of patients.” 

Read the entire press release on the partnership


Novo Nordisk's operating profit increased by 11% in Danish kroner and by 5%

oral semaglutide

Bagsværd, Denmark, 1 November 2019 Sales increased by 9% in Danish kroner and by 5% at CER to DKK 89.6 billion. Sales in International Operations increased by 13% in Danish kroner (11% at CER), driven by growth in all regions.

  • Sales in North America Operations increased by 6% in Danish kroner (decreased by 1% at CER).
  • Sales within Diabetes and obesity increased by 9% to DKK 75.5 billion (6% at CER), driven by Diabetes growing 4% at CER and Obesity growing 50% at CER. Sales within Biopharmaceuticals increased by 8% to DKK 14.1 billion (4% at CER).
  • Sales of Ozempic® were DKK 6,872 million and Ozempic® thereby reached blockbuster status. Ozempic® has now been launched in 24 countries. In the USA, the new-to-brand prescription market share for Ozempic® is now 37%, bringing Novo Nordisk's combined GLP-1 new-to-brand prescription market share to 54%.
  • In September 2019, Novo Nordisk received the US Food and Drug Administration (FDA) approval of Rybelsus® (semaglutide tablets) for treatment of adults with type 2 diabetes and Rybelsus® has now been made available in the USA.
  • For the 2019 outlook, sales growth is now expected to be 5-6% at CER (previously 4-6% at CER), while operating profit growth is still expected to be 4-6% at CER.

Lars Fruergaard Jørgensen, president and CEO: "We're very satisfied with the sales growth for the first nine months of 2019, which was driven by all regions in International Operations and growth across our therapy areas Diabetes, Obesity and Biopharmaceuticals. During the third quarter of 2019, we have reached two very important milestones: the US FDA approval of Rybelsus® and the blockbuster status of Ozempic® following the successful launch in the USA; two major events that emphasise the strength of our current and future GLP-1 franchise.”

Read the full announcement

Scaling up China’s fight against type 2 diabetes

China's fight against type 2 diabetes

China is facing a diabetes crisis, with more than one in 10 people living with the condition. The Chinese government, however, is fighting back with ambitious plans to deploy the latest technology to bring the epidemic under control, as Novo Nordisk CEO Lars Fruergaard Jørgensen saw for himself during a recent visit.

Read CEO Lars Fruergaard Jørgensen's account from his visit to China


The technology behind tablets

production Denmark

What if medicines injected by millions could be delivered in tablets? After almost 100 years of delivering injectable therapies, Novo Nordisk’s R&D team is finding answers to this enduring question. Chief Science Officer Mads Krogsgaard Thomsen is leading the way and he reflects on the magnitude of the scientific challenge and the progress made in his laboratories.

Read Mads' reflections


Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact 

Circular for zero

Novo Nordisk intends to achieve the target to use only renewable electricity in its global production facilities by 2020. The announcement on 30 April followed a new investment in a 672-acre solar panel installation, roughly the size of 500 football fields, in North Carolina, US, which will provide power to Novo Nordisk’s entire US operations from early 2020. Novo Nordisk is the first pharmaceutical company in RE100 to use only renewable electricity in production. RE100 is a collaborative, global initiative of businesses committed to using 100% renewable electricity.

Read more about Circular for Zero and download the full press release on the environmental ambitions 


Red Cross and Novo Nordisk partner to tackle chronic care in humanitarian crises

The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally; support for ICRC’s and DRC’s health programmes; 2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.

Read CEO Lars Fruergaard's reflections and more about the partnership



Full-year results for 2019

When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years. 

Watch the documentary, 'Safely in the Rainbow', on YouTube

Financial results 2019

1 November - third quarter 


Novo Nordisk in brief

Defeat NCDs

Zeana Massoud Said has type 1 diabetes. Zeana lives in Tanzania

The Danish Government and Novo Nordisk have announced grants of 3 and 5 million US dollars respectively to the Defeat-NCD Partnership. The aim is to raise 100 million dollars to fund mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries.

Read more details in the press release